Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical outcomes after swicth from etanercept to etanercept biosimilar (SB4) in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthrits:- DANBIO registry study

Trial Profile

Clinical outcomes after swicth from etanercept to etanercept biosimilar (SB4) in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthrits:- DANBIO registry study

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2018

At a glance

  • Drugs Etanercept (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biogen
  • Most Recent Events

    • 05 Nov 2018 Results assessing treatment outcomes in Etanercept-treated patients who switched to the Biosimilar Etanercept or maintained Etanercept, published in the Annals of the Rheumatic Diseases
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2018 Results (n=1641) assessing one year follow up presented at the 19th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top